Asceneuron SA
Asceneuron SA is a clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative diseases. Their lead asset, ASN51, is an oral small molecule OGA inhibitor designed to slow the progression of Alzheimer's disease by preventing tau protein aggregation. The company is advancing ASN51 into Phase 2 clinical development.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $100M
Date: 16-Jul-2024
Investors: Novo Holdings, EQT Life Sciences - LSP Dementia Fund, OrbiMed, SR One, M Ventures, Sofinnova Partners, GSK Equities Investments Limited, Johnson & Johnson Innovation - JJDC, Inc
Markets: Biotechnology, Pharmaceuticals, Alzheimer's Disease, Neurodegenerative Diseases
HQ: Lausanne, Vaud, Switzerland
Founded: 2012
Website: https://www.asceneuron.com/
LinkedIn: https://www.linkedin.com/company/asceneuron-sa
Twitter: https://twitter.com/asceneuron_sa
Crunchbase: https://www.crunchbase.com/organization/asceneuron
Leave a Comment
Comments
No comments yet.